文献速递乳腺癌放疗

重复保乳手术联合术中放疗治疗局部复发乳腺癌的II期试验

Feasibility and safety of repeat breast-conserving surgery with intraoperative irradiation for local breast carcinoma recurrences: A phase 2 trial.
PubMed 文献 · Radiother Oncol · 2026-04-17

BACKGROUND AND PURPOSE: The RE-IORT prospective, multicenter, single-arm phase II trial (NCT02386371) evaluated the feasibility and safety of repeat breast-conserving surgery (BCS) combined with focal reirradiation using intraoperative radiotherapy (IOReIrr) in patients with loca…

要点

  • 12个月无≥2级乳腺纤维化率为90.6%(95%CI 79.3-96.9)。
  • 60个月局部无复发生存率81.2%,无乳房切除生存率92.3%。
  • 术中对再照射作为二次保乳一部分(单日治疗)可行、安全且耐受良好。

核心结论

  • 对晚期局部复发乳腺癌选定患者,二次保乳联合术中再照射(单日治疗)可行、安全且耐受良好。
  • 研究提示在「单日治疗」与挽救性乳房切除之间共享决策是安全可行的选择。

研究设计与样本

  • RE-IORT为前瞻性、多中心、单臂II期试验(NCT02386371),评估重复保乳联合术中局灶再照射的可行性与安全性。
  • 入组患者为全乳放疗后≥5年乳房内复发,且具低危特征:单灶T1N0、非小叶组织学、1-2级、雌激素受体阳性、HER2阴性。
  • 主要终点为保乳联合术中再照射后12个月无≥2级乳腺纤维化,采用CTCAE v4.0报告。

主要发现

  • 术中再照射后12个月,48例未发生乳腺纤维化,为90.6%(95%CI 79.3-96.9)。
  • 随访期间3例在第二次保乳联合术中再照射后出现新局部复发。
  • 36个月和60个月局部无复发生存率分别为96.8%(95%CI 85.2-99.0)和81.2%(95%CI 65.2-90.3)。
  • 36个月和60个月无乳房切除率分别为94.2%(95%CI 83.1-98.1)和92.3%(95%CI 80.7-97.0)。

关键数值与推荐

  • 主要终点达标:12个月无≥2级乳腺纤维化率90.6%(95%CI 79.3-96.9)。
  • 60个月局部无复发生存率81.2%(95%CI 65.2-90.3),无乳房切除率92.3%(95%CI 80.7-97.0)。

临床怎么用

  • 对全乳放疗后≥5年、单灶T1N0、非小叶、1-2级、ER阳性、HER2阴性的乳房内复发患者,可考虑二次保乳联合术中再照射。
  • 术中再照射作为二次保乳的一部分为单日治疗,可与挽救性乳房切除进行共享决策。

局限性

  • 仅纳入低危特征选定患者,结论不能外推至其他复发人群。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: The RE-IORT prospective, multicenter, single-arm phase II trial (NCT02386371) evaluated the feasibility and safety of repeat breast-conserving surgery (BCS) combined with focal reirradiation using intraoperative radiotherapy (IOReIrr) in patients with locally recurrent breast carcinoma. PATIENTS AND METHODS: Eligible patients had in-breast recurrence ≥5 years after whole-breast radiotherapy, with low-risk features (unifocal T1N0, non-lobular histology, grade 1-2, estrogen receptor-positive, HER2-negative). The primary endpoint was the absence of grade ≥2 breast fibrosis at month 12 post-BCS + IOReIrr, reported using the Common Terminology Criteria for Adverse Events, version 4.0. Secondary endpoints were cumulative incidence of local relapse, local relapse-free/distant metastasis-free/disease-free/overall/mastectomy-free survival, quality of life, definitive cosmetic results and satisfaction. RESULTS: Fifty-three of the sixty-six patients enrolled from January 2015 to April 2018 were retained for the analysis (median follow-up of 59 months). At month 12 post-IOReIrr, 48 patients had not developed breast fibrosis (90.6% [95% CI: 79.3-96.9]). During the follow-up, three patients presented a new local relapse after the second BCS + IOReIrr. The 36-month and 60-month local recurrence-free survival rates were 96.8% [95% CI: 85.2-99.0] and 81.2% [95% CI: 65.2-90.3], respectively. The 36-month and 60-month mastectomy-free rates were 94.2% [95% CI: 83.1-98.1] and 92.3% [95% CI: 80.7-97.0], respectively. CONCLUSIONS: Intraoperative reirradiation as part of a second BCS (one-day treatment) is feasible, safe, and well-tolerated in selected patients with late local breast cancer recurrence (i.e. <2 cm. estrogen receptor-positive and node-negative). These findings suggests that shared decision-making between 'one-day treatment' and salvage mastectomy is a safe and viable option. TRIAL REGISTRATION: NCT02386371 (https://clinicaltrials.gov/study/ NCT02386371).

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Lemanski C, Houvenaeghel G, Gourgou S, et al. Feasibility and safety of repeat breast-conserving surgery with intraoperative irradiation for local breast carcinoma recurrences: A phase 2 trial. Radiother Oncol. 2026. PMID: 42001960. doi:10.1016/j.radonc.2026.111538

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。